Clinical trial
AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)
To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers.
To assess the tolerability of four and a half days treatment of AZD5363
Category | Value |
---|---|
Study start date | 2014-01-16 |